Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY J-IVUS: Alirocumab in Japanese ACS Patients
NCT02984982Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hypercholesterolemia and acute coronary syndrome (ACS) comparing Alirocumab with Standard of Care (2 arms). Primary endpoint: Percent Change From Baseline in Normalized Total Atheroma Volume at 36 weeks. Started Nov 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemiaacute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02984982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02984982.